1.
The double challenge of resistant hypertension and chronic kidney disease
by Rossignol, Patrick, Prof
The Lancet (British edition), 2015, Vol.386 (10003), p.1588-1598
2.
From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century
by Blacher, Jacques, Prof
The Lancet (British edition), 2016, Vol.388 (10043), p.530-532
3.
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
by Weber, Michael A, Prof
The Lancet (British edition), 2009, Vol.374 (9699), p.1423-1431
4.
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
by Zannad, Faiez, Prof
The Lancet (British edition), 2015, Vol.385 (9982), p.2067-2076
5.
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
by Weber, Michael A, Prof
The Lancet (British edition), 2013, Vol.381 (9866), p.537-545
6.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis...
by Bakris, George L, Dr, Prof
The Lancet (British edition), 2010, Vol.375 (9721), p.1173-1181
